Medical marijuana in neurology

References

• Institute of Medicine (US); Joy JE, Watson SJ, Benson JA. editors. Marijuana and medicine: assessing the science base. Washington (DC): National Academies Press (US); 1999. PMID 25101425
   Google Scholar
• Koppel BS, Brust JCM, Fife T, et al. Systematic review: efficacy and safety of medical marijuana in selected neurologic disorders. Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology 2014;82(17):1556-63
   PubMed Web of Science ®Google Scholar
• Borgelt LM, Franson KL, Nussbaum AM, Wang GS. The Pharmacologic and Clinical Effects of Medical Cannabis. Pharmacotherapy 2013;33(2):195-209
   PubMed Web of Science ®Google Scholar
• Gold Standard, Inc. Marijuana, Medical. Clinical Pharmacology. database online Available from: www.clinicalpharmacology.com [Last Accessed: 15 March 2014]
   Google Scholar
• Seamon MJ, Fass JA, Maniscalco-Feichtl M, Abu-Shraie NA. Medical Marijuana and the developing role of the pharmacist. Am J Health-Syst Pharm 2007;64:1037-44
   PubMed Web of Science ®Google Scholar
• Ben Amar M. Cannabinoids in medicine: a review of their therapeutic potential. J Ethnopharmacol 2006;105:1-25
   PubMed Web of Science ®Google Scholar
• Kumar RN, Chambers WA, Pertwee RG. Pharmacological actions and therapeutic uses of cannabis and cannabinoids. Anaesthesia 2001;56:1059-68
   PubMed Web of Science ®Google Scholar
• Pertwee RG. Cannabinoid pharmacology: the first 66 years. Br J Pharmacol 2006;147(suppl 1):S163-71
   PubMed Web of Science ®Google Scholar
• Pertwee RG, Howlett AC, Abood ME, et al. International union of basic and clinical pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB and CB. Pharmacol Rev 2010;62:588-631
   PubMed Web of Science ®Google Scholar
• Ibrahim MM, Porreca F, Lai J, et al. CB2 cannabinoid receptor activation produces antinociception by stimulating peripheral release of endogenous opioids. Proc Natl Acad Sci 2005;102:3093-8
   PubMed Web of Science ®Google Scholar
• Agurell S, Halldin M, Lindgren JE, et al. Pharmacokinetics and metabolism of delta 1-tetrahydrocannabinol and other cannabinoids with emphasis on man. Pharmacol Rev 1986;38:21-43
   PubMed Web of Science ®Google Scholar
• Cunha JM, Carlini EA, Pereira AE, et al. Chronic administration of cannabidiol to healthy volunteers and epileptic patients. Pharmacology 1980;21:175-85
   PubMed Web of Science ®Google Scholar
• Ames FR, Cridland S. Anticonvulsant effect of cannabidiol. S Afr Med J 1986;69:14
   PubMed Web of Science ®Google Scholar
• Gloss D, Vickrey B. Cannabinoids for epilepsy. Cochrane Database Syst Rev 2012;6:CD009270
   PubMed Web of Science ®Google Scholar
• Hill TD, Cascio MG, Romano B, et al. Cannabidivarin-rich cannabis extracts are anticonvulsant in mouse and rat via a CB1 receptor-independent mechanism. Br J Pharmacol 2013;170(3):679-92
   PubMed Web of Science ®Google Scholar
• Jones NA, Glyn SE, Akiyama S, et al. Cannabidiol exerts anti-convulsant effects in animal models of temporal lobe and partial seizures. Seizure 2012;21:344-5
   PubMed Web of Science ®Google Scholar
• Consroe PF, Benedito MA, Leite JR, et al. Effect of cannabidiol on behavioral seizures caused by convulsant drugs or current in mice. Eur J Pharmacol 1982;83:293
   PubMed Web of Science ®Google Scholar
• Jones NA, Hill AJ, Smith I, et al. Cannabidiol displays antiepileptiform and antiseizure properties in vitro and in vivo. J Pharmacol Exp Ther 2010;332:569-77
   PubMed Web of Science ®Google Scholar
• American Epilepsy Society. www.aesnet.org/sites/default/files/file_attach/AboutAES/PositionStatements/AES%20Position%20on%20Medical%20Marijuana.pdf [Last accessed 25 August 2014]
   Google Scholar
• Ward T. Migraine diagnosis and pathophysiology. Continuum Lifelong Learning Neurol 2012;18:753-63
   Google Scholar
• Greco R, Gasperi V, Maccarrone M, Tassolleri C. The endocannabinoid system and migraine. Exp Neurol 2010;224:85-91
   PubMed Web of Science ®Google Scholar
• Juhsz G, Lazary J, Chase D, et al. Variations in the cannabinoid receptor 1 gene predispose to migraine. NeurosciLett 2009;461:116-20
   PubMed Web of Science ®Google Scholar
• Akerman S, Kaube H, Goadsby PJ. Anandamide is able to inhibit trigeminal neurons using an in vivo model of trigeminovascular-mediated nociception. J Pharmacol Exp Ther 2003;309:56-63
   Web of Science ®Google Scholar
• Akerman S, Holland PR, Goadsby PJ. Cannabinoid (CB1) receptor activation inhibits trigeminovascular neurons. J Pharmacol Exp Ther 2007;320:64-71
   PubMed Web of Science ®Google Scholar
• Sarchielli P, Pini LA, Coppola F, et al. Endocannabinoids in chronic migraine: CSF findings suggest a system failure. Neuropsychopharmacology 2007;32:1384-90
   PubMed Web of Science ®Google Scholar
• Cupini LM, Bari M, Battista N, et al. Biochemical changes in the endocannabinoid system are expressed in platelets of female but not male migraineurs. Cephalalgia 2006;26:277-81
   PubMed Web of Science ®Google Scholar
• Van der Schueren BJ, Van Laere K, Gerard N, et al. Interictal type 1 cannabinoid receptor binding is increased in female migraine patients. Headache 2011;52:433-40
   PubMed Web of Science ®Google Scholar
• Brian M. Cannabinoids and hallucinogens for headache. Headache 2013;53:447-58
   PubMed Web of Science ®Google Scholar
• Robbins MS, Tarshich S, Solomon S, Grosberg BM. Cluster attacks responsive to recreational cannabis and dronabinol. Headache 1999;49:914-16
   Google Scholar
• Leroux E, Taifas I, Valade D, et al. Use of Cannabis among 139 cluster headache sufferers. Cephalalgia 2013;33:208-13
   PubMed Web of Science ®Google Scholar
• Schwarz S, Knorr C, Geiger H. Complementary and alternative medicine for multiple sclerosis. Mult Scler 2008;14:1113-19
   PubMed Web of Science ®Google Scholar
• Yadav V, Bever C, Bowen J, et al. Summary of evidence-based guideline: complementary and alternative medicine in multiple sclerosis: Report of the Guideline Development Subcommittee of the American Academy of. Neurology Neurology 2014;82:1083-92
   PubMed Web of Science ®Google Scholar
• Zajicek J, Fox P, Sanders H, et al. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre, randomised placebo controlled trial. Lancet 2003;362:1517-26
   PubMed Web of Science ®Google Scholar
• Fox P, Bain PG, Glickman S, et al. The effect of cannabis on tremor in patients with multiple sclerosis. Neurology 2004;62:1105-9
   PubMed Web of Science ®Google Scholar
• Zajicek JP, Hobart JC, Slade A, for MUSEC Research Group. Multiple sclerosis and extract of cannabis: results of the MUSEC trial. J Neurol Neurosurg Psychiatry 2012;83:1125-32
   PubMed Web of Science ®Google Scholar
• Novotna A, Mares J, Ratcliffe S, et al. A randomized double blind placebo controlled, parallel group, enriched design study of nabiximols (Sativex®) as add-on therapy in subjects with refractory spasticity caused by multiple sclerosis. Eur J Neurol 2011;18:1122-31
   PubMed Web of Science ®Google Scholar
• Collin C, Davies P, Mutiboko IK, Ratcliffe S; Sativex Spasticity in MS Study Group. Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis. Eur J Neurol 2007;14:290-6
   PubMed Web of Science ®Google Scholar
• Kavia RB, De Ridder D, Constantinescu CS, et al. Randomized controlled trial of Sativex to treat detrusor overactivity in multiple sclerosis. Mult Scler 2010;11:1349-59
   Google Scholar
• Corey-Bloom J, Wolfson T, Gamst A, et al. Smoked cannabis for spasticity in multiple sclerosis: a randomized, placebo-controlled trial. CMAJ 2012;184:1143-50
   PubMed Web of Science ®Google Scholar
• Greenberg HS, Werness SA, Pugh JE, et al. Short-term effects of smoking marijuana on balance in patients with multiple sclerosis and normal volunteers. Clin Pharmacol Ther 1994;55:324-8
   PubMed Web of Science ®Google Scholar
• Dworkin RH, O’Connor AB, Audette J, et al. Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. Mayo Clin Proc 2010;85:s3-14
   PubMed Web of Science ®Google Scholar
• Dixon WE. The pharmacology of Cannabis indica. Br Med J 1899;2:1354-7
   Google Scholar
• Herkenham M, Lynn AB, Johnson MR, et al. Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J Neurosci 1991;111:563-83
   Google Scholar
• Fox WA, McIntyre P, et al. Peripheral Nerve injury induces cannabinoid receptor 2 protein expression in rat sensory neurons. Neuroscience 2005;135:235-45
   PubMed Web of Science ®Google Scholar
• Rahn EJ, Hohmann AG. Cannabinoids as pharmacotherapies for neuropathic pain: from the bench to the bedside. Neurotherapeutics 2009;6(4):713-37
   PubMed Web of Science ®Google Scholar
• Toperoff EW, Vaida F, et al. Smoked medicinal cannabis for neuropathic pain in HIV: a randomized, crossover clinical trial. Neuropsychopharmocology 2009;34:672-80
   PubMed Web of Science ®Google Scholar
• Jay CA, Shade SB, et al. Cannabis in painful HIV-associated sensory neuropathy. Neurology 2007;68(7):515-21
   PubMed Web of Science ®Google Scholar
• Marcotte WT, Deutsch R, et al. Low dose vaporized cannabis significantly improves neuropathic pain. L Pain 2013;14(2):136-48
   PubMed Web of Science ®Google Scholar
• Marcotte WT, Tsodikov A, et al. A randomized, placebo-controlled, crossover trial of cannabis cigarettes in neuropathic pain. J Pain 2008;9(6):506-21
   PubMed Web of Science ®Google Scholar
• Abood ME, Aggarwal SK, et al. Cannabis and amyotrophic lateral sclerosis: hypothetical and practical applications, and a call for clinical trials. Am J Hosp Palliat Care 2010;27(5):347-56
   PubMed Web of Science ®Google Scholar
• The ALS Untangled Group. ALS Untangled No. 16: cannabis. Amyotrophic Lateral Sclerosis 2012;13:400-4
   PubMedGoogle Scholar
• Hong WS, Witting A, et al. Cannabinol delays symptom onset in SOD1 (G93A) transgenic mice without affecting survival. Amyotroph Lateral Scler Other Motor Neuron Disord 2005;6(3):182-4
   PubMedGoogle Scholar
• McAllister SD, Rizvi G, et al. Amyotrophic lateral sclerosis: delayed disease progression in mice by treatment with a cannabinoid. Amyotroph Lateral Scler Other Motor Neuron Disord 2004;5(1):33-9
   PubMedGoogle Scholar
• Amtmann D, Weydt P, Johnson KL, et al. Survey of cannabis use in patients with amyotrophic lateral sclerosis. Am J Hosp Palliat Care 2004;21:95-104
   PubMedGoogle Scholar
• Egertová M, Elphick MR. Localisation of cannabinoid receptors in the rat brain using antibodies to the intracellular C-terminal tail of CB. J Comp Neurol 2000;422(2):159-71
   PubMed Web of Science ®Google Scholar
• Long LE, Chesworth R, Huang XF, et al. Behavioural comparison of acute and chronic Delta9-tetrahydrocannabinol and cannabidiol in C57BL/6JArc mice. Int J Neuropsychopharmacol 2010;13:861-76
   PubMed Web of Science ®Google Scholar
• Meschler JP, Conley TJ, Howlett AC. Cannabinoid and dopamine interaction in rodent brain: effects on locomotor activity. Pharmacol Biochem Behav 2000;67:567-73
   PubMed Web of Science ®Google Scholar
• Sagredo O, García-Arencibia M, de Lago E, et al. Cannabinoids and neuroprotection in basal ganglia disorders. Mol Neurobiol 2007;36(1):82-91
   PubMed Web of Science ®Google Scholar
• Gowers W. A manual of diseases of the nervous system. P. Blakiston Son and Co; Philadelphia PA: 1888
   Google Scholar
• Venderová K, Růzicka E, Vorísek V. Survey on cannabis use in Parkinson’s disease: subjective improvement of motor symptoms. Survey on Cannabis Use in Parkinson’s Disease. Mov Disord 2004;19(9):1102-6
   PubMed Web of Science ®Google Scholar
• Lotan I, Treves TA, Roditi Y, Djaldetti R. Cannabis (medical marijuana) treatment for motor and non-motor symptoms of Parkinson disease: an open-label observational study. Clin Neuropharmacol 2014;37:41-4
   PubMed Web of Science ®Google Scholar
• Fox SH, Henry B, Hill M, et al. Stimulation of cannabinoid receptors reduced levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate model of Parkinson’s disease. Mov Disord 2002;17:1180-7
   PubMed Web of Science ®Google Scholar
• Conti LH, Johannesen J, Musty R, et al. In: Chesher G, Consroe P, Musty R, editors. Marijuana: An international research report. National campaign against drug abuse monograph series no. 7. Canberra: Autralian Government Publishing Service; 1988. 153-6
   Google Scholar
• Carroll CB, Bain PG, Teare L, et al. Cannabis for dyskinesia in Parkinson disease: a randomized double-blind crossover study. Neurology 2004;63:1245-50
   PubMed Web of Science ®Google Scholar
• Sierzdan K, Fox SH, Hill M, et al. Cannabinoids reduce levodopa-induced dyskinesia in Parkinson’s disease: a pilot study. Neurology 2001;57:2108-11
   PubMed Web of Science ®Google Scholar
• Sagredo O, Pazos MR, Valdoelivas S, Fernandez-Ruiz J. Cannabinoids: novel medicines for the treatment of Huntington’s disease. Recent Pat CNS Drug Discov. 2012;7(1):41-8
   Google Scholar
• Cosroe P, Laguna J, Allender J, et al. Controlled clinical trial of cannabinoid in Huntington’s Disease. Pharmacol Biochem Behav 1991;40:701-8
   PubMedGoogle Scholar
• Huntington Study Group. Unified Huntington’s disease rating scale: reliability and consistency. Mov Disord 1996;2:136-42
   Google Scholar
• Curtis A, Mitchell I, Patel S, et al. A pilot study using nabilone for symptomatic treatment of Huntington’s disease. Mov Disord 2009;24:2254-9
   PubMed Web of Science ®Google Scholar
• Uribe Roca MC, Micheli F, Viotti R. Cannabis sativa and dystonia secondary to Wilson’s disease.Mov Disord 2005;20(1):113-15
   Google Scholar
• Consroe P, Sandyk R, Snider SR. Open label evaluation of cannabidiol in dystonic movement disorders. Int J Neurosci 1986;30(4):277-82
   PubMed Web of Science ®Google Scholar
• Fox SH, Kellett M, Moore AP, et al. Randomised, double-blind, placebo-controlled trial to assess the potential of cannabinoid receptor stimulation in the treatment of dystonia. Mov Disord 2002;17(1):145-9
   PubMed Web of Science ®Google Scholar
• Müller-Vahl KR, Schneider U, Koblenz A, et al. Treatment of Tourette’s syndrome with Δ-9-tetrahydrocannabinol (THC): a randomized crossover trial. Pharmacopsychiatry 2002;35:57-61
   PubMed Web of Science ®Google Scholar
• Müller-Vahl KR, Schneider U, Prevedel H, et al. Δ9-tetrahydrocannabinol (THC) is effective in the treatment of tics in Tourette syndrome: a 6-week randomized trial. J Clin Psychiatry 2003;64:459-65
   PubMed Web of Science ®Google Scholar
• Gates PJ, Albertella L, Copeland J. The effects of cannabinoid administration on sleep: a systemic review of human studies. Sleep Med Rev 2014. Available from: http://dx.doi.org/10.1016/i.smrv.2014.02.005
   Google Scholar
• Green B, Kavanagh D, Young R. Being stoned: a review of self-reported cannabis effects. Drug Alcohol Rev 2003;22:453-60
   PubMed Web of Science ®Google Scholar
• Allsop DJ, Norberg MM, Copeland J, et al. The cannabis withdrawal scale development: patterns and predictors of cannabis withdrawal and distress. Drug Alcohol Depend 2011;119:123-9
   PubMed Web of Science ®Google Scholar
• Bonn-Miller MO, Babson KA, Vandrey R. Using cannabis to help you sleep: heightened frequency of medical cannabis use among those with PTSD. Drug Alcohol Depend 2014;136:162-5
   PubMed Web of Science ®Google Scholar
• Walsh Z, Callaway R, Belle-Isle L, et al. Cannabis for therapeutic purposes: patient characteristics, access, and reasons for use. Int J Drug Policy 2013;24:511-16
   PubMed Web of Science ®Google Scholar
• Zvolensky MJ, Bernstein A, Marshall EC. Anxiety vulnerability factors and disorders and tobacco and marijuana use and disorders: emerging theory and research explicating their relations. Addict Behav 2008;33(11):1383-4
   PubMed Web of Science ®Google Scholar
• Bolla KI, Lesage SR, Gamaldo CE, et al. Sleep disturbance in heavy marijuana users. Sleep 2008;31:901-8
   PubMed Web of Science ®Google Scholar
• Babson KA, Bonn-Miller MO. Sleep Disturbances: implications for Cannabis Use, Cannabis Use Cessation, and Cannabis Use Treatment. Curr Addict Rep 2014;1:109-14
   Google Scholar
• Fagan SG, Campbell VA. The influence of cannabinoids on generic traits of neurodegeneration. Brit J Pharmacol 2014;171:1347-60
   PubMed Web of Science ®Google Scholar
• Aso E, Ferrer I. Cannabinoids for treatment of Alzheimer’s disease: moving toward the clinic. Front Pharmacol 2014;5:37-47
   PubMed Web of Science ®Google Scholar
• Solas M, Francis PT, Franco R, et al. CB2 receptor and amyloid pathology in frontal cortex of Alzheimer’s disease patients. Neurobiol Aging 2013;34:805-8
   PubMed Web of Science ®Google Scholar
• Esposito G, De Filippis D, Carnuccio R, et al. The marijuana component cannabidiol inhibits beta-amyloid-induced tau protein hyperphosphorylation through Wnt/beta-catenin pathway rescue in PC12 cells. J Mol Med 2006;84:253-8
   PubMed Web of Science ®Google Scholar
• Eubanks LM, Rogers CJ, Beuscher AE. 4th, et al. A molecular link between the active component of marijuana and Alzheimer’s disease pathology. Mol Pharm 2006;3:773-7
   PubMed Web of Science ®Google Scholar
• Bachmeier C, Beaulieu-Abdelahad D, Mullan M, et al. Role of the cannabinoid system in the transit of amyloid beta across the blood brain barrier. Mol Cell Neurosci 2013;56:255-62
   PubMed Web of Science ®Google Scholar
• Hampson AJ, Grimaldi M, Lolic M, et al. Neuroprotective antioxidants from marijuana. Ann N Y Acad Sci 2000;899:274-82
   PubMed Web of Science ®Google Scholar
• Martin-Moreno AM, Brera B, Spuch C, et al. Prolonged oral cannabinoid administration prevents neuroinflammation, lowers beta-amyloid levels and improves cognitive performance in TgAPP2576 mice. J Neuroinflamm 2012;9:8
   PubMed Web of Science ®Google Scholar
• Abdel-Salam OME, Salem NA, et al. Cannabis-induced impairment of learning and memory: effect of different nootropic drugs. EXCLI J 2013;12:193-214
   PubMed Web of Science ®Google Scholar
• Volkow ND, Baler RD, Compton WM, et al. Adverse Health Effects of Marijuana Use. N Engl J Med 2014;70:2219-27
   Google Scholar
• Meier MH, Caspi A, Ambler A, et al. Persistent cannabis users show neuropsychological decline from childhood to midlife. Proc Natl Acad Sci USA 2012;109(40):E2657-64
   PubMed Web of Science ®Google Scholar
• Cheng D, Low JK, Logge W, et al. Chronic cannabidiol treatment improves social and object recognition in double transgenic APPswe/PS1ΔE9 mice. Psychopharm (Berl) 2014. [Epub ahead of print]
   Web of Science ®Google Scholar
• Woodward MR, Harper DG, Stolyar A, et al. Dronabinol for the Treatment of Agitation and Aggressive Behavior in Acutely Hospitalized Severely Demented Patients with Non-cognitive Behavioral Symptoms. Am J Geri Psych 2014;22:415-19
   PubMed Web of Science ®Google Scholar
• Zajicek JP, Sanders HP, Wright DE, et al. Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up. J Neurol Neurosurg Psych 2005;76:1664-9
   PubMed Web of Science ®Google Scholar
• Bergamaschi MM, Queiroz RH, Zuardi AW, Crippa JA. Safety and side effects of cannabidiol, a Cannabis sativa constituent. Curr Drug Saf 2011;6:237-49
   PubMedGoogle Scholar
• Frisher M, Crome I, Martino O, Croft P. Assessing the impact of cannabis use on trends in diagnosed schizophrenia in the United Kingdom from 1996 to 2005. Schizophr Res 2009;113:123-8
   PubMed Web of Science ®Google Scholar
• Proal AC, Fleming J, Galvez-Buccollini JA, Delisi LE. A controlled family study of cannabis users with and without psychosis. Schizophr Res 2014;152:283-8
   PubMed Web of Science ®Google Scholar
• Lindsay AC, Foale RA, Warren O, et al. Cannabis as a precipitant of cardiovascular emergencies. Int J Cardiol 2005;104:230-2
   PubMed Web of Science ®Google Scholar
• Moore BA, Augustson EM, Moser RP, et al. Respiratory effects of marijuana and tobacco use in a U.S. sample. J Gen Intern Med 2005;20:3307
   Web of Science ®Google Scholar
• Pletcher MJ, Vittinghoff E, Kalhan R, et al. Association between marijuana exposure and pulmonary function over 20 years. JAMA 2012;307:173-81
   PubMed Web of Science ®Google Scholar
• Russo E, Mathre ML, Byrne A, et al. Chronic cannabis use in the Compassionate Investigational New Drug program: an examination of benefits and adverse effects of legal clinical Cannabis. J Clin Psychiatry 2002;2:3-57
   Google Scholar
• Kirby T, Barry AE. Alcohol as a gateway drug: a study of US 12th graders. J Sch Health 2012;82:371-9
   PubMed Web of Science ®Google Scholar
• Battistella G, Fornari E, Annoni JM, et al. Long-term effects of cannabis on brain structure. Neuropsychopharmacology 2014;39(9):2041-8
   PubMed Web of Science ®Google Scholar
• Kuster JK, Lee S, et al. “Cannabis Use Is Quantitatively Associated with Nucleus Accumbens and Amygdala Abnormalities in Young Adult Recreational Users”. J Neurosci 2014;34(16):5529-38
   PubMed Web of Science ®Google Scholar